TScan Therapeutics (TCRX) Non-Current Deffered Revenue (2020 - 2025)
TScan Therapeutics (TCRX) posted quarterly Non-Current Deffered Revenue of $501000.0 for Q1 2025, down 89.47% year-over-year from $4.8 million in Q1 2024, and down 59.79% quarter-over-quarter from $1.2 million in Q4 2024.
TScan Therapeutics (TCRX) Non-Current Deffered Revenue (2020 - 2025) Analysis & Trends
TScan Therapeutics (TCRX) has reported Non-Current Deffered Revenue for 5 consecutive years, with $501000.0 the latest figure, recorded in Q1 2025.
- In Q1 2025, Non-Current Deffered Revenue fell 89.47% year-over-year to $501000.0; the TTM figure through Mar 2025 stood at $501000.0 (down 89.47% YoY), while the FY2024 annual figure was $1.2 million, down 77.84% from the prior year.
- Non-Current Deffered Revenue retreated to $501000.0 in Q1 2025 per TCRX's latest filing, from $1.2 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $7.8 million in Q3 2023 and bottomed at $501000.0 in Q1 2025.
- Historically, Non-Current Deffered Revenue has averaged $4.0 million across 4 years, with a median of $4.0 million in 2024.
- Annual changes were most pronounced in 2024 — Non-Current Deffered Revenue tumbled 48.26% — and 2025, when it slumped 89.47%.
- TScan Therapeutics' Non-Current Deffered Revenue stood at $1.5 million in 2021, then jumped by 275.55% to $5.6 million in 2023, then slumped by 77.84% to $1.2 million in 2024, then plunged by 59.79% to $501000.0 in 2025.
- Business Quant data shows TCRX's Non-Current Deffered Revenue at $501000.0 in Q1 2025, $1.2 million in Q4 2024, and $3.7 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 501,000.00 |
| Dec 31, 2024 | 1.25 Mn |
| Sep 30, 2024 | 3.68 Mn |
| Jun 30, 2024 | 3.96 Mn |
| Mar 31, 2024 | 4.76 Mn |
| Dec 31, 2023 | 5.62 Mn |
| Sep 30, 2023 | 7.76 Mn |
| Jun 30, 2023 | 7.64 Mn |
| Dec 31, 2021 | 1.50 Mn |
| Sep 30, 2021 | 2.84 Mn |
| Jun 30, 2021 | 4.56 Mn |
| Dec 31, 2020 | 8.82 Mn |